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Abstract
Background: Panax notoginseng saponins (PNS), the main active components of Radix Notoginseng, has been
used for treating atherosclerosis, cerebral infarction, and cerebral ischemia. Ginsenosides Rg1, ginsenoside Rb1, and
notoginsenoside R1 are the main contributors of biological activities, determination of these three saponins is very
important for the in vivo evaluation of PNS. The present study aims to develop a liquid chromatography-tandem
mass spectrometry (LC-MS/MS) method for the simultaneous quantification of ginsenosides Rg1, ginsenoside Rb1,
and notoginsenoside R1. The use of this method was exemplified in pharmacokinetic study of beagle dog plasma
after oral administration of PNS.
Methods: Liquid chromatography-tandem mass spectrometry (LC/MS/MS) method was combined with solid-phase
extraction (SPE). This setup was used to determine simultaneously the three major PNS (ginsenoside Rg1,
ginsenoside Rb1, and notoginsenoside R1) in beagle dog plasma. Tandem mass spectrometry was performed using
electrospray ionization in the positive ion mode.
Results: The lower limits of quantification were 0.5 ng/mL for notoginsenoside R1, 0.82 ng/mL for ginsenoside Rg1,
and 1.10 ng/mL for ginsenoside Rb1. The calibration curves for the three saponins were linear over the
concentration ranges 2.64-264 ng/mL (r
2 = 0.9967, P = 0.003), 3.6-360 ng/mL (r
2 = 0.9941, P = 0.004), and 18.7-1870
ng/mL (r
2 = 0.9912, P = 0.004) for notoginsenoside R1, ginsenoside Rg1, and ginsenoside Rb1, respectively. Within
these concentration ranges, the relative standard deviation (RSD) of intra- and interday assays for the three PNS
from beagle dog plasma samples were less than 12%.
Conclusions: This LC/MS/MS method in combination with SPE is useful in the pharmacokinetic study of PNS, such
as the simultaneous determination of saponins in beagle dog plasma after oral administration.
Background
Panax notoginseng saponins (PNS), the main active
components of Radix Notoginseng [1], are used for treat-
ing atherosclerosis [2], cerebral infarction [3], and cere-
bral ischemia [4]. The major bioactive saponins of Radix
Notoginseng [5] are ginsenoside Rg1,g i n s e n o s i d eR b 1,
and notoginsenoside R1 (Figure 1). In addition, notogin-
senoside R1, a saponin unique to Panax notoginseng, has
anti-thrombus activity [6]. Thus, determination of these
three saponins is very important for the in vivo monitor-
ing and evaluation of PNS.
Determination of the limit of quantification (LOQ) of
PNS in biological samples is a great challenge for in vivo
research. The reported quantitative methods included
thin-layer chromatography [7,8], high-performance liquid
chromatography (HPLC) with UV detection [9,10], fluor-
escence detection [11], gas chromatography-mass spec-
trometry [12], and liquid chromatography-mass
spectrometry (LC/MS) with electrospray positive [13] or
negative [14] ionization. Although many methods were
developed to determine the saponins of PNS in extracts,
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values were unsatisfactorily determined in biological
samples. For example, the LOQ values of ginsenoside Rg1
and ginsenoside Rb1 were higher than 500 ng/mL in rat
biological samples detected by thin-layer chromatography
[7,8]; 60 and 5.0 ng/mL, respectively, in rat urine samples
by HPLC-UV [15]; and 10.0 ng/mL using a 100- μl
plasma sample by LC/MS with negative ionization [10].
There is no report on the determination of notoginseno-
side R1 after oral administration of PNS or the simulta-
neous determination of ginsenosides Rg1 and Rb1 and
notoginsenoside R1 in plasma after oral administration of
PNS. Thus, it is necessary to develop a sensitive method
to determine the saponins in PNS, especially in biological
samples.
As LC-MS is useful in drug metabolism and pharma-
cokinetic studies on active components in Chinese med-
icines [16-19], we developed a LC-MS method for drug
metabolism and pharmacokinetic study of ginsenoside
Rg3 and ginsenoside Rh2,a n do u rf i n d i n g ss h o w e dt h a t
LC-MS and MS/MS methods are sensitive, specific, and
convenient for such ginsenoside studies [17-19].
Multiple reactions monitoring (MRM) mass spectro-
metry has special advantages for quantitative analysis of
analyte: it is specific and selective technology that can
avoid contaminants in the biological samples. In the
present study, we aims to develop a liquid chromatogra-
phy-tandem mass spectrometry (LC-MS/MS) multiple
reactions monitoring method combined with solid-phase
extraction preparation of samples for the simultaneous
quantification of ginsenosides Rg1,g i n s e n o s i d eR b 1,a n d
notoginsenoside R1 and to conduct a pharmacokinetic
study of beagle dog plasma after oral administration of
PNS.
Methods
Chemicals and reagents
Acetonitrile and methanol (HPLC grade) were pur-
chased from Fisher Scientific (NewJersey, USA). Extract-
Clean C18 (solid-phase extraction) cartridge columns
were purchased from the Alltech Company (Deerfield,
USA). Ginsenosides Rg1 and Rb1 and notoginsenoside
R1 were purchased from the National Institute for the
Control of Pharmaceutical and Biological Products (Beij-
ing, China), and PNS extract was purchased from the
Institute of Medicinal Plant Development, Yunnan
Branch (Yunnan Province, China). The contents of gin-
senosides Rg1 and Rb1 and notoginsenoside R1 in the
PNS extract were 37%, 36%, and 10%, respectively,
according to HPLC analysis. Glipizide (internal stan-
dard) was kindly provided by Professor Jifen Guo at the
Academy of Military Medical Sciences (Beijing, China).
Instrumental analysis
The HPLC system consisted of a quaternary LC pump
of Agilent 1100 series, from Agilent Technology (Wald-
bronn, Germany), with a degasser and an autosampler.
The mobile phase consisted of 10 mM ammonium acet-
ate solution, 0.1% n-butyl-amine,10% methanol in water
(A) and methanol (B). The flow rate was kept at 0.2
mL/min for a total run time of eight minutes. The sys-
tem was run with a gradient program of 50% B to 90%
Figure 1 Chemical structures of ginsenoside Rb1, ginsenoside Rg1, and notoginsenoside R1
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The samples were introduced into the electrospray ion
source of a triple-stage quadrupole mass spectrometer
Finnigan TSQ 7000 with API-2 ion source and perfor-
mance kit (Thermo Electron, Dreieich, Germany). Elec-
trospray ionization interface parameters were as follows:
spray voltage: 4.0 kV; sheath gas (N2): 8 units; capillary
heater temperature: 300°C. Multiple reactions monitor-
ing measurements were performed at a multiplier vol-
tage of 1.2 kV.
Animals
T h r e em a l eb e a g l ed o g s ,w e i g h i n g1 0 - 1 2k g ,w e r ep u r -
chased from Tongli Laboratory Animals Center (Beijing,
China) for the animal experiments. Experimental ani-
mals were maintained in accordance with internationally
guidelines for laboratory animal use [20], and the study
was approved by the Beijing Animal Care Committee
(Beijing China).
Sample preparation
For the assay, a 0.5 mL plasma sample was loaded and
drawn through by gravity on a solid-phase extraction
cartridge (1 mL, packed with 100 mg of 40 μm octade-
cyl silica) that was preconditioned by passing through
2 mL of methanol followed by 2 mL of water before
loading. Then the solid-phase cartridge was washed with
2 mL of water, 2 mL of 20% (v/v) aqueous methanol
solution, and 2 mL of methanol. The final methanol
elute was collected and 10 μl of internal standard was
added to it. The elute was thereafter evaporated at 40°C
to dryness under a stream of nitrogen. The residue was
dissolved in 100 μl of 50% (v/v) aqueous methanol solu-
tion. A 20 μl sample was injected into the HPLC system
for analysis.
Method validation
Calibration curve and quality control sample preparation
Primary mixed stock solutions of notoginsenoside R1,
ginsenoside Rg1, and ginsenoside Rb1 were prepared in
methanol/water (1:1, v/v). Working standard solutions
of the three saponins were prepared by combining the
aliquots of each primary solution and diluting with
methanol/water (1:1, v/v). The working solution for
internal standard (0.1 μg/mL) was prepared using
methanol. All stock solutions were stored at 4°C in poly-
propylene tubes in the dark.
Beagle dog plasma calibration standards of the three
saponins were prepared by spiking standard solutions with
various concentrations of drug-free beagle dog plasma.
Standard solutions of six different concentrations of the
three saponins were obtained: 2.64, 5.28, 13.2, 26.4, 52.8,
and 264 ng/mL for notoginsenoside R1; 3.60, 7.20, 18.0,
36.0, 72.0, and 360 ng/mL for ginsenoside Rg1; and 18.7,
37.4, 93.5, 187, 374, and 1870 ng/mL for ginsenoside Rb1.
Three calibration curves were established by determining
the peak area ratio (analyte/internal standard) versus the
saponin concentrations in samples processed as described
in Sample preparation.
Quality control samples were prepared in bulk by add-
ing 50 μl of the appropriate working standard solutions
to blank beagle dog plasma. The quality control samples
at 2.8, 14, and 140 ng/mL for notoginsenoside R1;3 . 8 ,
19, and 190 ng/mL for ginsenoside Rg1; and 18, 180,
and 900 ng/mL for ginsenoside Rb1 were stored at -20°C
until analysis.
Accuracy and precision
Batches of quality control samples were analyzed on
four different days to validate the method. In each
batch, quality control samples were assayed in sets of
six replicates to evaluate the accuracy and intra- and
interday precision. The accuracy and relative standard
deviation (RSD) were used to evaluate the method.
Recovery and sensitivity
The relative recovery of this method was determined by
comparing the concentration calculated from the cali-
bration curve to the known concentration. Recovery was
evaluated with four replicates, and samples were pre-
pared as the quality control samples.
The LOQ values were measured using a series of
diluted standard plasma samples. For the concentration
to be accepted as the LOQ, the signal-to-noise ratio had
to be greater than or equal to five and the percent
deviation for the analyte concentration and the relative
standard deviation had to be within 20%.
Pharmacokinetic study
PNS extract was administered orally at a dose of 90 mg/
kg to beagle dogsthat had been fasting but had free
access to water for 18 hours prior to the experiment.
Each blood sample (3 mL) was transferred to a hepari-
nized glass tube at 0 hr, 0.5 hr, 1 hr, 2 hr, 3 hr, 4 hr,
6h r ,8h r ,1 0h r ,1 2h r ,1 6h r ,2 4h r ,3 6h r ,4 8h ra n d
72 hr after administration and immediately centrifuged
at 1500 × g for 15 minutes at 8-10°C. The plasma was
then transferred to another glass tube and stored at -20°C
until analysis.
Results and discussion
Sample preparation
Sugar moieties are extracted incompletely into organic
solvents. Therefore, solid-phase extraction was used to
remove excess ingredients in plasma and achieve good
selectivity. When the concentration of methanol was
below 20%, the three saponins were strongly absorbed
by the C18 stationary phase, while the interfering com-
pounds in plasma could be eluted under this condition.
The excellent selectivity of solid-phase extraction helped
to improve the LC-MS/MS analysis.
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Page 3 of 6Figure 2 HPLC chromatograms of (a) notoginsenoside R1; (b) ginsenoside Rg1; (c) ginsenoside Rb1; and (d) internal standard
(glipizide).
Figure 3 Tandem mass spectra (daughter ion scans) of (a) internal standard (glipizide); (b) notoginsenoside R1 parent ion;
(c) ginsenoside Rg1; and (d) ginsenoside Rb1.
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The three saponins and internal standard in plasma
were completely separated within six minutes without
significant interference (Figure 2), demonstrating the
specificity of this method. The retention times were as
follows: 1.56, 1.67, 3.87, and 1.80 minutes for notoginse-
noside R1,g i n s e n o s i d eR g 1,g i n s e n o s i d eR b 1,a n di n t e r -
nal standard, respectively.
MS/MS transitions monitored in the positive ion
mode were m/z 1007 ® m/z 423 for notoginsenoside
R1 (MW 932), m/z 875 ® m/z 423 for ginsenoside Rg1
(MW 800), m/z 1183 ® m/z 487 for ginsenoside Rb1
(MW 1108), and m/z 494 ® m/z 369.1 for internal
standard. MS/MS spectra (daughter ion scans) of the
three saponins and internal standard are shown in
Figure 3.
In this method, standard curves are linear over the
range of 2.64-264 ng/mL for notoginsenoside R1, 3.60-
360 ng/mL for ginsenoside Rg1, and 18.7-1870 ng/mL
for ginsenoside Rb1, with all correlation coefficients lar-
ger than 0.99. The LOQ values are 0.5 mL for notogin-
senoside R1, 0.82 ng/mL for ginsenoside Rg1,a n d
1.10 ng/mL for ginsenoside Rb1.T h er e s u l t so ft h ea n a -
lysis are shown in Table 1.
T h er e s u l t so ft h ea s s a yo fp r e c i s i o na n da c c u r a c ya r e
shown in Table 2. The relative standard deviation of the
Table 1 Calibration curves of the three Panax notoginseng saponins in beagle dog plasma
Analyte Standard curves (linear) Pr
2 Test range (ng/mL) Limit of quantification (ng/mL)
NotoginsenosideR1 Y = 0.0011X+0.0004 0.003 0.9967 2.64–264 0.50
Ginsenoside Rg1 Y = 0.0009X+0.0007 0.004 0.9941 3.60–360 0.82
Ginsenoside Rb1 Y = 0.0016X+ 0.0283 0.004 0.9912 18.7–1870 1.10
Note: Y, peak area ratio (analyte/internal standard); X, concentration of analyte in plasma (ng/mL)
Table 2 Intra- and interday variability for the assay of the three Panax notoginseng saponins in beagle dog plasma
(n =6 )
Spiked conc.
(ng/mL)
Intraday Interday
Measured conc. (ng/mL) RSD (%)
a Accuracy (%)
b Measured conc. (ng/mL) RSD (%) Accuracy (%)
Notoginsenoside R1
2.8 2.8 1.27 100.0 2.68 1.49 95.71
14 13.9 0.76 99.29 12.89 9.62 92.1
140 148 8.22 105.7 131.67 10.11 105.7
Ginsenoside Rg1
3.8 3.6 5.13 94.7 3.96 11.96 104.2
19 17.6 3.65 92.6 18.3 8.95 96.3
190 197.3 6.59 103.8 193.7 7.66 101.7
Ginsenoside Rb1
18 18.1 3.07 100.6 17.6 5.36 96.11
180 165.3 2.73 91.83 179.7 5.05 99.50
900 912.67 3.90 101.3 871.3 2.38 96.87
Note:
aRelative standard deviation;
bAccuracy (%) = [1–(nominal concentration – mean of measured concentration)/nominal concentration] × 100
Table 3 Recovery of the three Panax notoginseng
saponins from beagle dog plasma (n =4 )
Analyte Spiked conc.
(ng/mL)
Recovery (%)
a, b RSD (%)
c
Notoginsenoside R1 2.8 96.0 ± 6.72 6.99
14 104.0 ± 7.71 7.41
140 102.3 ± 7.82 7.82
Ginsenoside Rg1 3.8 99.9 ± 6.89 6.90
19 102.4 ± 6.73 6.57
190 98.96 ± 8.06 8.14
Ginsenoside Rb1 18 102.6 ± 9.85 9.60
180 101.1 ± 10.26 9.14
900 105.0 ± 8.32 7.92
Note:
aRecovery (%) = [1 – (spiked concentration – measured concentration)/
spiked concentration] × 100;
bValues are the mean ± SD (n = 4);
cRelative
standard deviation
Table 4 Pharmacokinetic parameters of the three
saponins
Parameters Notoginsenoside
R1
Ginsenoside
Rg1
Ginsenoside Rb1
Cmax
(ng/mL)
37.57 ± 24.55 95.57 ± 69.30 1080.00 ± 186.82
Tmax (h) 2.67 ± 1.15 2.63 ± 1.15 8.67 ± 6.43
T1/2 (h) 3.35 ± 0.55 4.55. ± 1.22 18.274 ± 2.55
AUC 107.02 ± 17.39 233.42 ± 87.69 35178.68 ± 12236.26
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shown in Table 3.
Pharmacokinetics study of the three saponins
The pharmacokinetic parameters are listed in Table 4.
In this study, notoginsenoside R1 and ginsenoside Rg1
could hardly be detected after 24 hours, whereas ginse-
noside Rb1 could still be detected at four days. Thus,
the half-life of ginsenoside Rb1 is much longer than
those of ginsenoside Rg1 and notoginsenoside R1.
Conclusions
This LC-MS/MS assay combined with solid-phase
extraction was simple, rapid, highly sensitive, and pre-
cise for the determination of notoginsenoside R1, ginse-
noside Rg1, and ginsenoside Rb1 in beagle dog plasma
samples after oral administration of PNS at 90 mg/kg.
Although thin-layer chromatography and HPLC-UV
methods had been used to study the pharmacokinetics
of saponins in PNS [5,6], the specific and more sensitive
LC-MS/MS method allows for the simultaneous deter-
mination of the three saponins and the quantification of
PNS in biological samples, making this as a promising
method for the in vivo study of PNS.
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